Sun Pharma gains 3%; hits new high on UBS 'Buy' rating, sees more upside

Q: How long will it take to read this news story?

The story "Sun Pharma gains 3%; hits new high on UBS &#039;Buy&#039; rating, sees more upside" has 706 words across 25 sentences, which will take approximately 3 - 6 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Sun Pharma gains 3%; hits new high on UBS &#039;Buy&#039; rating, sees more upside" was covered 8 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 270 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22749301</li><li>URL: https://beamstart.com/news/sun-pharma-gains-3-hits-17274308214509</li></ul>

Business Standard Logo Business Standard 8h ago

Sun Pharma gains 3%; hits new high on UBS 'Buy' rating, sees more upside - Business Standard

Quick Summary:

UBS has a target price of Rs 2,450 on Sun Pharma and expects it to record the highest growth in the near-term and the medium-term via a ramp-up of the specialty drug pipelline.

Analysts at Elara Securities feel that it could be three to four quarters before all the warning letters/import alerts by US FDA are lifted and the business gets on a growth path.

Analysts at UBS expect the company's specialty portfolio revenues to double over the next four years to over $2 billion.